Most uveitis-related vision loss is the result of chronic inflammation of the posterior segment of the eye (i.e., intermediate, posterior, and panuveitis). Although noninfectious anterior uveitis is typically treated successfully with topical corticosteroids, noninfectious uveitis of the posterior segment (NIU-PS) can be more difficult to manage. Corticosteroids (e.g., topical, systemic) remain the clinical mainstay for this type of uveitis, but the use of other immunomodulators, such as tumor necrosis factor (TNF)-alpha inhibitors, has become increasingly widespread. Given the competitive NIU-PS therapy market, it is essential to understand the use of current therapies in the nuanced treatment algorithm using real-world data.
Geographies: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Humira, Remicade, other TNF-alpha inhibitors, Ozurdex, Iluvien, Retisert, Lotemax, Durezol, Triesence, prednisolone, prednisone
Key analysis provided:
Brand/therapy usage across longitudinal patient sample
Newly diagnosed patient analysis
Treatment initiation and progression
Line of therapy analysis
Combination therapy analysis
Source of business for recently treated patients
Persistency and compliance analysis
Product-level patient flowcharts
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.